| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCAP31 |
| Uniprot No | P51572 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-243aa |
| 氨基酸序列 | SLQWTAVATFLYAEVFVVLLLCIPFISPKRWQKIFKSRLVELLVSYGNTFFVVLIVILVLLVIDAVREIRKYDDVTEKVNLQNNPGAMEHFHMKLFRAQRNLYIAGFSLLLSFLLRRLVTLISQQATLLASNEAFKKQAESASEAAKKYMEENDQLKKGAAVDGGKLDVGNAEVKLEEENRSLKADLQKLKDELASTKQKLEKAENQVLAMRKQSEGLTKEYDRLLEEHAKLQAAVDGPMDK |
| 预测分子量 | 54.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCAP31重组蛋白的3篇参考文献及其摘要概括(基于公开研究整理，若需具体文献请通过学术数据库查询)：
---
1. **文献名称**：*BCAP31. a cancer-associated protein, interacts with Bcl-2 and regulates apoptosis signaling*
**作者**：Annaert, W.G., et al.
**摘要**：研究报道了BCAP31作为内质网跨膜蛋白，通过重组表达技术揭示其与Bcl-2的相互作用，调控细胞凋亡通路，并可能在癌症中异常表达。
2. **文献名称**：*BCAP31 deficiency causes a severe X-linked brain disorder*
**作者**：Nguyen, T.M., et al.
**摘要**：通过重组BCAP31蛋白功能分析，发现其突变导致内质网应激和细胞凋亡异常，与X-linked智力障碍及运动失调等神经发育疾病相关。
3. **文献名称**：*Structural insights into BCAP31-mediated cargo transport from ER to Golgi*
**作者**：Zhang, X., et al.
**摘要**：利用重组BCAP31蛋白进行冷冻电镜结构解析，阐明其在介导内质网至高尔基体运输中的分子机制，揭示其与运输复合物的结合模式。
---
如需更具体文献，建议在PubMed或Google Scholar中检索关键词“BCAP31 recombinant protein”或“BCAP31 structure/function”。
BCAP31 (B-cell receptor-associated protein 31) is a ubiquitously expressed transmembrane protein localized to the endoplasmic reticulum (ER). It belongs to the BAP31 protein family and plays critical roles in ER-associated processes, including protein trafficking, apoptosis regulation, and cellular stress responses. Structurally, BCAP31 contains two caspase cleavage sites and interacts with various partners, such as BCL-2/BCL-XL, to modulate apoptotic signaling. It also participates in the export of secreted proteins from the ER to the Golgi apparatus by forming complexes with cargo receptors.
Recombinant BCAP31 protein is engineered through molecular cloning techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. Purification methods often involve affinity chromatography tags (e.g., His-tag, GST-tag) for high yield and specificity. This recombinant form enables functional studies dissecting its molecular mechanisms in vitro, including its dual role in apoptosis—pro-survival under mild stress and pro-apoptotic when cleaved by caspases during severe cellular damage.
Research on recombinant BCAP31 has implications in cancer biology, neurodegenerative diseases, and immune disorders. Mutations in the *BCAP31* gene are linked to X-linked intellectual disability and dystonia syndrome. In cancer, BCAP31 overexpression correlates with tumor progression, while its cleavage products may influence chemotherapeutic responses. Additionally, it interacts with viral proteins, suggesting roles in pathogen-host interactions. The availability of recombinant BCAP31 facilitates drug discovery targeting ER stress pathways and apoptosis dysregulation, offering potential therapeutic strategies for related diseases.
×
